GENENTECH INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENENTECH INC, and when can generic versions of GENENTECH INC drugs launch?
GENENTECH INC has eight approved drugs.
There are fifty-five US patents protecting GENENTECH INC drugs.
There are eight hundred and thirty-six patent family members on GENENTECH INC drugs in fifty-four countries and sixty-seven supplementary protection certificates in nineteen countries.
Summary for GENENTECH INC
| International Patents: | 836 |
| US Patents: | 55 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 8 |
| Drug Master File Entries: | 7 |
| Patent Litigation for GENENTECH INC: | See patent lawsuits for GENENTECH INC |
Drugs and US Patents for GENENTECH INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | 8,013,002 | ⤷ Sign Up | ⤷ Sign Up | |||
| Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | 9,029,356 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-002 | Oct 24, 2018 | RX | Yes | No | 11,261,198 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | 8,383,150 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Genentech Inc | EVRYSDI | risdiplam | FOR SOLUTION;ORAL | 213535-001 | Aug 7, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 10,188,637 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-001 | Oct 24, 2018 | DISCN | Yes | No | 11,306,106 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for GENENTECH INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | 9,561,217 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENENTECH INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
International Patents for GENENTECH INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 3428170 | ⤷ Sign Up |
| Eurasian Patent Organization | 029542 | ⤷ Sign Up |
| Peru | 20170128 | ⤷ Sign Up |
| Brazil | 112012013155 | ⤷ Sign Up |
| South Korea | 20080046673 | ⤷ Sign Up |
| Eurasian Patent Organization | 032466 | ⤷ Sign Up |
| Costa Rica | 20110243 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GENENTECH INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2620436 | 7/2021 | Austria | ⤷ Sign Up | PRODUCT NAME: BALOXAVIR MARBOXIL ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/20/1500 (MITTEILUNG) 20210108 |
| 1934174 | C20160012 00193 | Estonia | ⤷ Sign Up | PRODUCT NAME: KOBIMETINIIB;REG NO/DATE: EU/1/15/1048 24.11.2015 |
| 3107541 | 2021C/522 | Belgium | ⤷ Sign Up | PRODUCT NAME: ENTRECTINIB IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/20/1460 20200803 |
| 3107541 | 122021000032 | Germany | ⤷ Sign Up | PRODUCT NAME: ENTRECTINIB IN ALLEN DEM GRUNDPATENT ZUGRUNDE LIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/20/1460 20200731 |
| 2620436 | PA2021505,C2620436 | Lithuania | ⤷ Sign Up | PRODUCT NAME: BALOKSAVIRO MARBOKSILAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/20/1500 20210107 |
| 3143025 | 132021000000149 | Italy | ⤷ Sign Up | PRODUCT NAME: RISDIPLAM O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(EVRYSDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1531, 20210329 |
| 1934174 | 22/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: COBIMETINIB ALS EIN EINZELNES STEREOISOMER ODER ALS EINE MISCHUNG VON STEREOISOMEREN DAVON, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE UND SOLVATE, INSBESONDERE COBIMETINIB HEMIFUMARAT; REGISTRATION NO/DATE: EU/1/15/1048 (MITTEILUNG) 20151124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
